| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Senior VP Clinical Development
2 companies
Chu Yu-Waye is a Chief Medical Officer at FATE THERAPEUTICS INC with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $890K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | CTMX Cytomx Therapeutics, Inc. | Chief Medical Officer | Sell | 4,025 | $0.60 | $2,410.98 | -2.9% | +307.5% | +628.8% | |
| Apr 18, 2023 | FATE Fate Therapeutics Inc | Chief Medical Officer | Sell | 2,532 | $6.57 | $16,647.66 | -0.9% | -25.2% | -15.4% | |
| Jan 10, 2023 | FATE Fate Therapeutics Inc | Chief Medical Officer | Sell | 7,825 | $5.24 | $41,003.00 | -5.2% | -0.2% | -16.8% | |
| Apr 19, 2022 | FATE Fate Therapeutics Inc | Chief Medical Officer | Sell | 4,062 | $35.37 | $143,672.94 | -2.6% | -16.6% | -82.7% | |
| Jan 11, 2022 | FATE Fate Therapeutics Inc | Senior VP Clinical Development | Sell | 3,965 | $48.51 | $192,340.48 | -1.6% | -24.6% | -88.0% | |
| Dec 10, 2021 | FATE Fate Therapeutics Inc | Senior VP Clinical Development | Sale+OE | 7,500 | $51.46 | $385,947.94 | -0.8% | -27.8% | -61.6% | |
| Apr 16, 2021 | FATE Fate Therapeutics Inc | Senior VP Clinical Development | Sell | 3,275 | $83.30 | $272,809.00 | -1.6% | -5.5% | -56.3% |